Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTP (ID: DTI7UX6)

DTP Name Breast cancer resistance protein (ABCG2) DTP Info
Gene Name BCRP

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
127 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [1]
Aciclovir DMYLOVR Genital herpes 1A94 Approved [2]
Adefovir DMM278X N. A. N. A. Approved [3]
Alfuzosin DMZVMKF Benign prostatic hyperplasia GA90 Approved [4]
Apixaban DM89JLN Thrombosis DB61-GB90 Approved [5]
ARRY-162 DM1P6FR Melanoma 2C30 Approved [6]
Baricitinib DM4ONW5 Rheumatoid arthritis FA20 Approved [7]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [8]
Bicalutamide DMZMSPF Prostate cancer 2C82.0 Approved [9]
Brigatinib DM7W94S Anaplastic large cell lymphoma 2A90.A Approved [10]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [11]
Canagliflozin DMFRM1I Non-insulin dependent diabetes 5A11 Approved [12]
Cephalothin Sodium DM51Z9E Bacterial infection 1A00-1C4Z Approved [13]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [14]
Chlorothiazide DMLHESP Chronic heart failure BD1Z Approved [15]
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [16]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [14]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [17]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [18]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [19]
Cladribine DM3JDRP Hairy cell leukaemia 2A82.2 Approved [20]
Clofarabine DMCVJ86 Acute lymphoblastic leukaemia 2A85 Approved [20]
Dabrafenib DMX6OE3 Melanoma 2C30 Approved [21]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [22]
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [23]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [24]
Dehydroepiandrosterone sulfate DM4Q80H N. A. N. A. Approved [25]
Delavirdine DM3NF5G Human immunodeficiency virus infection 1C62 Approved [14]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [13]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [26]
Dipyridamole DMXY30O Atrial fibrillation BC81.3 Approved [27]
Dirithromycin DM0D9YJ Bacterial infection 1A00-1C4Z Approved [13]
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [28]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [29]
Eltrombopag DMOGFIX Thrombocytopenia 3B64 Approved [30]
Empagliflozin DMRF9YK Type-1 diabetes 5A10 Approved [31]
Entacapone DMLBVKQ Parkinson disease 8A00.0 Approved [32]
Entecavir DM7VTQO Hepatitis B virus infection 1E51.0 Approved [33]
Epirubicin DMPDW6T Solid tumour/cancer 2A00-2F9Z Approved [14]
Erlotinib DMCMBHA Adrenal gland neoplasm Approved [34]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [27]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [35]
Estrone sulfate DMVBIZL Atrophic vaginitis GA30.2 Approved [36]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [37]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [38]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [39]
Fluvastatin DM4MDJY Arteriosclerosis BD40 Approved [40]
Folic Acid DMEMBJC Colorectal carcinoma Approved [41]
Ganciclovir DM1MBYQ Cytomegalovirus infection 1D82 Approved [42]
Gefitinib DM15F0X Colon adenocarcinoma Approved [14]
Glibenclamide DM8JXPZ Diabetic complication 5A2Y Approved [43]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [44]
Grepafloxacin DMGLX0T Chronic bronchitis CA20.1 Approved [45]
Hesperetin DMKER83 High blood cholesterol level 5C80.00 Approved [46]
Hydroxychloroquine DMSIVND Chronic renal failure GB61.Z Approved [47]
Idarubicin DMM0XGL Acute myelogenous leukaemia 2A41 Approved [48]
Idelalisib DM602WT Chronic lymphocytic leukaemia 2A82.0 Approved [49]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [50]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [51]
Lamivudine DMI347A Chronic HBV infection 1E51.0Z Approved [52]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [53]
Leflunomide DMR8ONJ Arthritis FA20 Approved [54]
Lopinavir DMITQS0 Human immunodeficiency virus infection 1C62 Approved [14]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [55]
Mercaptopurine DMTM2IK Acute lymphoblastic leukaemia 2A85 Approved [3]
Metformin DM89QE1 Colorectal carcinoma Approved [56]
Methotrexate DM2TEOL Anterior urethra cancer Approved [57]
Mitoxantrone DMM39BF Acute myelogenous leukaemia 2A41 Approved [24]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [58]
Nicardipine DMCDYW7 High blood pressure BA00 Approved [14]
Nifurtimox DMSQLZJ Chagas disease IF53 Approved [59]
Nilotinib DM7HXWT Chronic myelogenous leukaemia 2A20.0 Approved [23]
Nitrofurantoin DM7PQIK Urinary tract infection GC08 Approved [60]
Norfloxacin DMIZ6W2 Acute gonococcal cervicitis Approved [61]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [14]
Olmesartan medoxomil DMWBHRY High blood pressure BA00 Approved [31]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [62]
Paclitaxel DMLB81S Breast carcinoma Approved [28]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [63]
Pantoprazole DMSVOCZ Gastrinoma 2C10.1 Approved [64]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [65]
Pemetrexed DMMX2E6 Central nervous system lymphoma 2B33.5 Approved [66]
Pirarubicin DMGTW1I Breast cancer 2C60-2C65 Approved [39]
Pitavastatin DMJH792 Hypercholesterolaemia 5C80.0 Approved [27]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [67]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [68]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [69]
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [14]
Prazosin DMCD9YG Benign prostatic hyperplasia GA90 Approved [70]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [35]
Pyrimethamine DM5X7VY Malaria 1F40-1F45 Approved [71]
Quercetin DM3NC4M Obesity 5B81 Approved [14]
Rabeprazole DMMZXIW Bacterial infection 1A00-1C4Z Approved [72]
Raltitrexed DMT9K8G Rectal adenocarcinoma 2B92 Approved [73]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [31]
Reserpine DM6VM38 Hypertension BA00-BA04 Approved [14]
Riboflavin DM8YMWE Acne vulgaris ED80 Approved [74]
Rifampin DMA8J1G Tuberculosis 1B10-1B1Z Approved [13]
Riluzole DMECBWN Amyotrophic lateral sclerosis 8B60.0 Approved [75]
Riociguat DMXBLMP Chronic thromboembolic pulmonary hypertension Approved [31]
Rivaroxaban DMQMBZ1 Deep vein thrombosis BD71 Approved [76]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [77]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [78]
Saquinavir DMG814N Human immunodeficiency virus infection 1C62 Approved [79]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [69]
Sofosbuvir DMQI86A Hepatitis C 1E51 Approved [31]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [80]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [81]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [80]
Talazoparib DM1KS78 Breast cancer 2C60-2C65 Approved [82]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [83]
Teniposide DMLW57T Acute lymphoblastic leukaemia 2A85 Approved [14]
Tenofovir DM1IS6U Chronic hepatitis B virus infection Approved [31]
Tenofovir alafenamide DMTQF4A Hiv infectious disease Approved [84]
Teriflunomide DMQ2FKJ Hyperlipidaemia 5C80 Approved [47]
Testosterone DM7HUNW Hot flushes GA30 Approved [85]
Tetracycline DMZA017 Acne vulgaris ED80 Approved [13]
Thioguanine DM7NKEV Acute lymphocytic leukaemia 2B33.3 Approved [3]
Topotecan DMP6G8T Central nervous system neoplasm Approved [86]
Trimetrexate DMDEA85 Toxoplasmosis 1F57 Approved [71]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [87]
Verteporfin DMIY6DB Choroidal neovascularization 9B76 Approved [88]
Vinblastine DM5TVS3 Advanced cancer 2A00-2F9Z Approved [28]
Vincristine DMINOX3 Acute lymphoblastic leukaemia 2A85 Approved [71]
VRX496 DMIO4V5 Acquired immune deficiency syndrome 1C62.3 Approved [14]
YN-968D1 DMMP3Y2 Breast cancer 2C60-2C65 Approved [89]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 127 Approved Drug(s)
29 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Camptothecin DM6CHNJ Solid tumour/cancer 2A00-2F9Z Phase 3 [90]
Edotecarin DM3ZL7D Gastric adenocarcinoma 2B72 Phase 3 [73]
Exatecan DMCA7FN Solid tumour/cancer 2A00-2F9Z Phase 3 [73]
Karenitecin DMCRGY4 Lung cancer 2C25.0 Phase 3 [73]
Nolatrexed DMOF0CA Solid tumour/cancer 2A00-2F9Z Phase 3 [71]
Resveratrol DM3RWXL Giant cell arteritis 4A44.2 Phase 3 [41]
Synthetic hypericin DMXU4ON Virus infection 1A24-1D9Z Phase 3 [91]
Genistein DM0JETC Menopause symptom GA30.0 Phase 2/3 [92]
9-AMINOCAMPTOTHECIN DMQXYRG Acquired immune deficiency syndrome 1C62.3 Phase 2 [73]
Bisantrene DMW76V0 N. A. N. A. Phase 2 [73]
CKD602 DMW9F1G Solid tumour/cancer 2A00-2F9Z Phase 2 [93]
CP-724714 DMUJ0W7 Lymphoma 2A80-2A86 Phase 2 [94]
DIFLOMOTECAN DM20ATW Solid tumour/cancer 2A00-2F9Z Phase 2 [73]
Flavopiridol DMKSUOI Acute myeloid leukaemia 2A60 Phase 2 [95]
Gimatecan DMSKMET Breast cancer 2C60-2C65 Phase 2 [73]
HPPH DM25PQB N. A. N. A. Phase 2 [96]
LE-SN38 DMW50NF Colorectal cancer 2B91.Z Phase 2 [97]
NSC-645809 DMPJQZG Breast cancer 2C60-2C65 Phase 2 [98]
Ortataxel DM1EK5D Solid tumour/cancer 2A00-2F9Z Phase 2 [14]
Oxfendazole DMSNL51 N. A. N. A. Phase 2 [99]
PEITC DMOMN31 Prostate cancer 2C82.0 Phase 2 [25]
PIRITREXIM DM276N1 Bladder cancer 2C94 Phase 2 [71]
UCN-01 DMUNJZB Non-small-cell lung cancer 2C25.Y Phase 2 [73]
BN-2629 DMA9MP5 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [100]
Taurocholic Acid DM2LZ8F Type-2 diabetes 5A11 Phase 1/2 [16]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [25]
Benzoylphenylurea DMMW4HV N. A. N. A. Phase 1 [101]
Mycophenolic acid glucuronide DM5O4X9 N. A. N. A. Phase 1 [58]
Sphingosine-1-phosphate DMJCQKA Acne vulgaris ED80 Phase 1 [102]
------------------------------------------------------------------------------------
⏷ Show the Full List of 29 Clinical Trial Drug(s)
7 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Parabis DMDKXYC N. A. N. A. Withdrawn from market [103]
BECATECARIN DMRQV8I Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 3 [104]
Befloxatone DMZIV6D Major depressive disorder 6A70.3 Discontinued in Phase 3 [105]
E-3040 DM35KZG Thrombosis DB61-GB90 Discontinued in Phase 2 [106]
Lurtotecan DMF1RTW Ovarian cancer 2C73 Discontinued in Phase 2 [25]
NB-506 DMGVYXB Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [73]
Rhodamine-123 DMQAK6T Prostate cancer 2C82.0 Discontinued in Phase 1 [107]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Discontinued Drug(s)
9 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Azidothymidine monophosphate DM3FLMR N. A. N. A. Preclinical [106]
Barasertib-hQPA DMTJZIL N. A. N. A. Preclinical [108]
BMS 536924 DMDJH2L N. A. N. A. Preclinical [109]
Enrofloxacin DMK6WIO N. A. N. A. Preclinical [110]
Homocamptothecin DMBQDA3 N. A. N. A. Preclinical [111]
N-desethyl sunitinib DM5ATJ0 N. A. N. A. Preclinical [112]
Pancratistatin DM3YUGA N. A. N. A. Preclinical [113]
Puromycin DMDKLB5 N. A. N. A. Preclinical [25]
Scutellarin DMJT1E5 N. A. N. A. Preclinical [114]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Preclinical Drug(s)
14 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Butanoic Acid DMTAJP7 Discovery agent N.A. Investigative [115]
Cholesterol DMR3J6S Discovery agent N.A. Investigative [35]
Chrysin DM7V2LG Discovery agent N.A. Investigative [14]
COUMESTROL DM40TBU Discovery agent N.A. Investigative [116]
daidzein DMRFTJX Discovery agent N.A. Investigative [116]
glycocholic acid DM0SXNM Discovery agent N.A. Investigative [16]
Hematoporphyrin DMVK36Q N. A. N. A. Investigative [117]
JNJ-7706621 DMHTYBS Discovery agent N.A. Investigative [118]
Mepacrine DMU8L7C Discovery agent N.A. Investigative [13]
phosphatidylserine DM76TSG Discovery agent N.A. Investigative [119]
Protoporphyrin IX DMWYE7A Discovery agent N.A. Investigative [73]
Tyrphostin ag-1478 DM87ZIH Discovery agent N.A. Investigative [19]
uric acid DMA1MKT Discovery agent N.A. Investigative [120]
[3H]estradiol-17beta-glucuronide DM3KJ45 Discovery agent N.A. Investigative [121]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 Investigative Drug(s)
Molecule Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

References

1 QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv Drug Deliv Rev. 2009 Jan 31;61(1):34-46.
2 Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity. Can J Physiol Pharmacol. 2011 Sep;89(9):675-80.
3 ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
4 In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol. 2011;(201):325-71.
5 Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013 Apr;41(4):827-35.
6 The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391.
7 Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01201-17.
8 Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacol Res. 2017 Jun;120:43-50.
9 Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11.
10 NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA.
11 Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol. 2010 Oct 1;80(7):1080-6.
12 In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096.
13 Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
14 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
15 ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions. Drug Metab Pharmacokinet. 2012;27(3):349-53.
16 Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83.
17 Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Mol Pharmacol. 2008 Mar;73(3):613-5.
18 Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93.
19 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
20 Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
21 Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64.
22 Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72.
23 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
24 Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
25 A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
26 Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
27 ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
28 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
29 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
30 Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects. Antimicrob Agents Chemother. 2012 Jun;56(6):2846-51.
31 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
32 Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors. Drug Metab Dispos. 2017 Dec;45(12):1282-1291.
33 Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
34 Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33.
35 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
36 ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9.
37 Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
38 Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
39 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
40 Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates. Pharm Res. 2015 May;32(5):1634-47.
41 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
42 Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population. In Vitro Cell Dev Biol Anim. 2010 Jun;46(6):497-501.
43 Glyburide transport across the human placenta. Obstet Gynecol. 2015 Mar;125(3):583-8.
44 Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2. J Biol Chem. 2010 May 28;285(22):16582-7.
45 Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos. 2007 Oct;35(10):1873-9.
46 Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun. 2004 Apr 23;317(1):269-75.
47 MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):779-87.
48 Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
49 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB09054)
50 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
51 Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol. 2006 Sep;58(3):374-83.
52 The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol. 2007 Nov;64(5):645-54.
53 The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008 Apr;36(4):695-701.
54 Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009 Jul;68(7):1201-7.
55 The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3279-86.
56 Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol. 2010 Apr;202(4):383.e1-7.
57 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
58 Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
59 The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein. Brain Res. 2012 Feb 3;1436:111-21.
60 The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol. 2005 May;67(5):1758-64.
61 Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006 Apr;34(4):690-5.
62 Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52.
63 Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71.
64 Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11.
65 Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53.
66 pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos. 2011 Sep;39(9):1478-85.
67 Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3):800-7.
68 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08901)
69 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
70 P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats. Brain Res. 2011 Jan 25;1370:238-45.
71 Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
72 Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9.
73 Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
74 Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol. 2007 Feb;27(4):1247-53.
75 Interactions between riluzole and ABCG2/BCRP transporter. Neurosci Lett. 2009 Mar 6;452(1):12-6.
76 Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):164-70.
77 ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):231-43.
78 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
79 Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem. 2010 Dec;115(6):1495-507.
80 Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
81 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
82 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB11760)
83 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
84 Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):465-472.
85 Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU Int. 2008 Dec;102(11):1694-9.
86 Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C. Eur J Pharmacol. 2010 Oct 10;644(1-3):41-8.
87 Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol. 2010 Jan;65(2):335-46.
88 The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007 Apr 15;13(8):2463-70.
89 Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010 Oct 15;70(20):7981-91.
90 The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010 Jan;24(1):146-9.
91 Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci. 2009 Dec;8(12):1716-23.
92 Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci. 2012 May;101(5):1888-97.
93 Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res. 2008 Nov;25(11):2601-12.
94 Multi-drug-resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors. ChemMedChem. 2009 Feb;4(2):188-95.
95 The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther. 2012 Sep;11(9):2033-44.
96 Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy. Mol Pharm. 2010 Oct 4;7(5):1789-804.
97 Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 2001 Nov 9;288(4):827-32.
98 C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells. Biochem Pharmacol. 2007 Jun 30;74(1):41-53.
99 Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos. 2005 May;33(5):614-8.
100 Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters. AAPS J. 2010 Dec;12(4):617-27.
101 American Association for Cancer Research.
102 Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem. 2010 Apr 2;285(14):10477-86.
103 Human and rat ABC transporter efflux of bisphenol a and bisphenol a glucuronide: interspecies comparison and implications for pharmacokinetic assessment. Toxicol Sci. 2012 Aug;128(2):317-25.
104 Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells. Cancer Chemother Pharmacol. 2009 Aug;64(3):575-83.
105 Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening. J Nucl Med. 2011 Mar;52(3):415-23.
106 Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005 May 11;7(1):E118-33.
107 Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo. Exp Mol Med. 2017 Mar 17;49(3):e303.
108 P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. BMC Cancer. 2011 Jun 16;11:254.
109 Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Mol Cancer Ther. 2011 Jan;10(1):117-25.
110 Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther. 2006 Aug;29(4):279-87.
111 ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007 Mar;26(1):39-57.
112 P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther. 2012 Apr;341(1):164-73.
113 Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Mol Pharmacol. 2009 Nov;76(5):946-56.
114 Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
115 The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein. Am J Physiol Cell Physiol. 2011 Nov;301(5):C984-94.
116 Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol. 2007 Oct;72(4):967-75.
117 Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharm Res. 2009 Feb;26(2):449-58.
118 Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol Cancer Ther. 2006 Oct;5(10):2459-67.
119 ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010 Apr 24;86(17-18):631-7.
120 Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS One. 2012;7(2):e30456.
121 Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites. Drug Metab Dispos. 2014 Apr;42(4):575-85.